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Night vision requires signaling from rod photoreceptors to adjacent bipolar cells in the retina. Mutations in the genes NYX and GRM6,
expressed in ON bipolar cells, lead to a disruption of the ON bipolar cell response. This dysfunction is present in patients with complete
X-linked and autosomal-recessive congenital stationary night blindness (CSNB) and can be assessed by standard full-ﬁeld electroretinog-
raphy (ERG), showing severely reduced rod b-wave amplitude and slightly altered cone responses. Although many cases of complete
CSNB (cCSNB) are caused by mutations in NYX and GRM6, in ~60% of the patients the gene defect remains unknown. Animal models
of human diseases are a good source for candidate genes, andwe noted that a cCSNB phenotype present in homozygous Appaloosa horses
is associated with downregulation of TRPM1. TRPM1, belonging to the family of transient receptor potential channels, is expressed in
ON bipolar cells and therefore qualiﬁes as an excellent candidate. Indeed, mutation analysis of 38 patients with CSNB identiﬁed ten
unrelated cCSNB patients with 14 different mutations in this gene. The mutation spectrum comprises missense, splice-site, deletion,
and nonsense mutations. We propose that the cCSNB phenotype in these patients is due to the absence of functional TRPM1 in retinal
ON bipolar cells.Congenital stationary night blindness (CSNB) is a group of
genetically and clinically heterogeneous retinal disorders.
The genes involved in the different forms of CSNB encode
proteins, which are conﬁned to the phototransduction
cascade or are important in retinal signaling from photore-
ceptors to adjacent bipolar cells.1 Most of the patients
with mutations in these genes show a typical electrophys-
iological phenotype characterized by an electronegative
waveform of the dark-adapted, bright-ﬂash electroretino-
gram (ERG), in which the amplitude of the b-wave is
smaller than that of the a-wave.2 This so-called Schubert-
Bornschein type of ERG response allows the discrimina-
tion of two subtypes of CSNB: incomplete (ic) (CSNB2A
[MIM 300071], CSNB2B [MIM 610427]) and complete (c)
(CSNB1A [MIM 310500], CSNB1B [MIM 257270].3 The
incomplete type is characterized by both a reduced rod
b-wave and substantially reduced cone response, due to720 The American Journal of Human Genetics 85, 720–729, Novemboth ON and OFF bipolar cell dysfunction, whereas the
complete type is associated with a drastically reduced rod
b-wave response but largely normal cone b-wave ampli-
tudes, due to ON bipolar cell dysfunction.4
In a considerable fraction of CSNB patients, mutations
have been identiﬁed by direct sequencing of candidate
genes or microarray analysis.5 However, from our CSNB
cohort, the phenotype in ~60% of the patients could not
be associated with mutations in known genes, indicating
that additional genes remain unidentiﬁed. Recently,
a type of CSNB in Appaloosa horses has been described.6,7
Affected animals initially showed reduced vision in dim
light conditions, which subsequently progressed to
reduced vision even in normal light conditions in severely
affected animals. No fundus abnormalities were present,
but strabismus and nystagmus were described. Electro-
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Figure 1. TRPM1 Isoforms and CSNB Mutations
Three isoforms of TRPM1 are presented: the 70þTRPM1 variant represents the previously published reference sequence (RefSeq
NM_002420.4), whereas the 92þTRPM1 and 109þTRPM1 isoforms were only recently identiﬁed.13 In comparison to 70þTRPM1, the
92þTRPM1 isoform contains 22 additional amino acids, and the 109þTRPM1 isoform contains 39 additional amino acids. The new
open reading frame of 92þTRPM1 is made up of the complete exon 2 with the initiation codon located in a new exon (exon 10). The
new ORF of 109þTRPM1 is made up of the complete exon 2 and a new exon (exon 0). Both new ORFs continue in the isoform
70þTRPM1, coding for 1625 and 1642 amino acids, respectively.the human Schubert-Bornschein type of ERG response.8
Furthermore, the photopic ﬂicker responses of affected
horses seemed to be similar when compared with those
of unaffected horses,6 suggesting a phenotype reminiscent
of cCSNB. Association studies of the coat coloring in these
horses revealed that this trait is directly linked with the
CSNB phenotype. Gene expression analysis of genes linked
to this disorder revealed that TRPM1 (MIM 603576), also
known as melastatin (MLSN1), was signiﬁcantly downre-
gulated in the retina and skin of affected animals. Thus,
it was proposed that TRPM1 is responsible for altering
bipolar signaling as well as melanocyte function, causing
both CSNB and the coat color phenotype in Appaloosa
horses.9 Studies in mice lacking Trpm1 revealed a severely
reduced b-wave in ERG recordings, similar to the Schu-
bert-Bornschein type of ERG response.10 These ﬁndings
support the hypothesis that this gene is important for
night vision.
TRPM1 is a member of the transient receptor potential
(TRP) channel family. These channels permit Ca2þ entry
into hyperpolarized cells, producing intracellular responses
linked to the phosphatidylinositol and protein kinase CThe Americansignal transduction pathway.11 Because of the downregula-
tion of TRPM1 in Appaloosa horses with CSNB, it was sug-
gested that this genemay play a role in neural transmission
in the human retina through changing cytosolic-free Ca2þ
levels in the retina inONbipolar cells. ThemGluR6 protein
(MIM 604096) of the ON bipolar cells is coupled to Gao
proteins (MIM 139311) and to TRPM1. TRPM1 might be
the cation channel that is downstream of the Gao protein
in the ON bipolar cells.9
Altogether, thephenotypeofAppaloosahorses, thedown-
regulation of TRPM1 in affected animals, and its localiza-
tion downstream of mGluR6 in ON bipolar cells rendered
this gene a good candidate. Thus, we screened this gene in
38 clinically diagnosed CSNB patients from different
centers in Europe and the United States (Belgium: Ghent;
France: Paris, Montpellier, and Lille; Germany: Berlin,
Freiburg, Giessen, and Tuebingen; Switzerland: Lausanne;
United States: Philadelphia, PA). Prior to this study, most
patients were excluded either for known mutations, by
a CSNB genotyping microarray, or for known CSNB genes
and additional candidate genes, by direct sequencing.5
Research procedures were conducted in accordance withJournal of Human Genetics 85, 720–729, November 13, 2009 721
Figure 2. Electrophysiologic Description of Patient CIC00238 with cCSNB, as an Example
Full-ﬁeld ERGs show typical ON bipolar pathway dysfunction: there are no detectable responses for the dark-adapted 0.01 ERG; dark-
adapted 3.00 and 12.0 ERGs show an a-wave with a normal amplitude and implicit time but a severely reduced b-wave, leading to an
electronegative waveform. Dark-adapted oscillatory potentials (OPs) are not detectable. Light-adapted 3.0 ERGs shownormal amplitudes
but implicit time shift for both the a-wave and the b-wave. The a-wave has a broadened trough, and there is a sharply rising b-wave
with no OPs. Light-adapted 3.0 ﬂicker ERGs show normal amplitudes but a broadened trough and a mildly delayed implicit time. These
photopic ERG appearances are characteristic of selective dysfunction of the ON bipolar pathway with OFF bipolar pathway preserva-
tion.31 This is further conﬁrmed with long-duration stimulations, which reveal a normal a-wave but a severely reduced ON-response
b-wave and a preserved OFF-response d-wave.722 The American Journal of Human Genetics 85, 720–729, November 13, 2009
Table 1. Patients with Likely Pathogenic TRPM1 Mutations
Index Patient,
Location, Family
Members Ethnicity Exon
Nucleotide
Exchange
Allele
State Protein Effect
Control
Alleles
(Mut/WT)
Phenotype
Index
CIC00238: Paris, France Portuguese-French 12 c.1418G>C hom? p.Arg473Pro 0/286 cCSNB, myopia,
nystagmus,
strabismus
unaff. father CIC03424 12 c.1418G>C het p.Arg473Pro
unaff. mother CIC03423 - no - -
unaff. sister CIC03421 - no - -
unaff. sister CIC03422 - no - -
aff. sister CIC03452 12 c.1418G>C hom? p.Arg473Pro cCSNB, myopia,
nystagmus,
strabismus
4497a, II-1: Tuebingen,
Germany
German 3 c.31C>T het p.Gln11X 0/352 cCSNB, nystagmus,
myopia
4 c.296T>C het p.Leu99Pro 0/224
unaff. father 4608, I-1 4 c.296T>C het p.Leu99Pro
unaff. mother 4610, I-2 3 c.31C>T het p.Gln11X
unaff. sister 4600, II-2 - no - -
unaff. sister 4712, II-4 3 c.31C>T het p.Gln11X
unaff. brother 4740, II-3 3 c.31C>T het p.Gln11X
691: Tuebingen, Germany Turkish 20 c.2567G>A hom? p.Trp856X 0/366 cCSNB, myopia,
nystagmus,
strabismus
8214: Tuebingen, Germany German 10 c.1197G>A het c.Pro399Pro/
splice defect?
0/350 cCSNB, myopia,
strabismus
26 c.3491delA het p.Gln1164ArgfsX31 0/266
CIC00612: Paris, France French 4 c.215A>G het p.Tyr72Cys 0/210 cCSNB, myopia,
nystagmus,
strabismus24 c.3094G>T het p.Glu1032X 0/370
unaff. mother: CIC03359 24 c.3094G>T het p.Glu1032X
unaff. brother: CIC03360 - no - -
23625a, II-3: Lausanne,
Switzerland
Italian 4 c.215A>G het p.Tyr72Cys 0/210 cCSNB, myopia
int4 c.428-3C>G het splice defect 0/298
unaff. father 23628, I-1 4 c.215A>G het p.Tyr72Cys
unaff. mother 23728, I-2 int4 c.428-3C>G het splice defect
unaff. brother CIC03365, II-1 - no -
unaff. brother CIC03364, II-2 4 c.215A>G het p.Tyr72Cys
758.01: Giessen, Germany German int20 c.2634þ1G>A het splice defect 0/366 cCSNB
27 c.3834C>T het p.Asn1278Asn 0/304
D0704708a, II-3: Ghent,
Belgiumb
Flemish-Belgian 2 c.1-27C>T
(70þTRPM1) or
c.40C>T
(92þTRPM1)
hom 50 UTR expression
defect or p.Arg14Trp
0/348 cCSNB, strabismus,
hypermetropia
unaff. father CIC03386, I-1 2 00 het 50 UTR expression
defect or p.Arg14Trp
unaff. mother D0704709, I-2 2 00 het 50 UTR expression
defect or p.Arg14Trp
unaff. sister CIC03389, II-1 2 00 het 50 UTR expression
defect or p.Arg14Trp
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Table 1. Continued
Index Patient,
Location, Family
Members Ethnicity Exon
Nucleotide
Exchange
Allele
State Protein Effect
Control
Alleles
(Mut/WT)
Phenotype
Index
unaff. sister CIC03390, II-2 2 00 het 50 UTR expression
defect or p.Arg14Trp
unaff. brother CIC03391, II-3 - no -
14101: Philadelphia, PA, USA Austrian-Russian-
Ashkenazi Jewish
18 c.2322T>A het p.Tyr774X 0/380 cCSNB, myopia
? ? - ?
unaff. father 19037 ? ? - ?
unaff. mother 19038 18 c.2322T>A het p.Tyr774X
10731: Berlin, Germany German 14 c.1622T>A het p.Met541Lys 0/214 cCSNB, myopia
? ? - ?
Index patients are presented in bold. Abbreviations are as follows: Mut, mutated; het, heterozygous; hom, homozygous; unaff., unaffected; aff., affected. CSNB
mutations are annotated according to the recommendation of the Human Genome Variation Society, with nucleotide position þ1 corresponding to the A of the
translation-initiation codon ATG in the cDNA nomenclature RefSeq NM_002420.4, 70þTRPM1. For Exon 0 and Exon 10, the respective A of the new translation
initiation codon ATG was used.
a See Figures 3A and 3B.
b 27533 Diagnostic: Zurich, Switzerland.institutional guidelines and the Declaration of Helsinki.
Prior to genetic testing, informed consent was obtained
from all patients and their family members. Ophthalmic
examination included best corrected visual acuity, slit724 The American Journal of Human Genetics 85, 720–729, Novemlamp examination, funduscopy,Goldmannkinetic perime-
try, full-ﬁeld ERG incorporating the ISCEV (International
Society for Clinical Electrophysiology of Vision) stan-
dards,12 fundus autoﬂuorescence, and optical coherenceFigure 3. TRPM1 Mutations and Cosegregation Analysis in Families with CSNB
(A) Electropherograms of three index patients provided as an example, showing TRPM1mutations, which are highlighted by an arrow.
Exonic sequence is shown in capital letters. Intronic sequence is shown in lowercase letters.
(B) Corresponding pedigrees of selected cCSNB patients with TRPM1 mutations and cosegregation in available family members. Filled
symbols represent affected individuals, and unﬁlled symbols represent unaffected persons. Squares indicate males, and circles indicate
females. Arrows reﬂect the index patients.ber 13, 2009
Table 2. Likely Non-Disease-Causing TRPM1 Variants Identified in Patients with CSNB
Exon Nucleotide Exchange Allele State Protein Effect Control Alleles (Mut/WT) Conclusion
0 c.16C>T het or hom p.Arg6Trp frequent in patients and controls new, but T occurs also in
Platypus; thus, SNP
10 c.1195C>A het p.Pro399Thr 8/350 SNP
26 c.3483G>C het p.Gln1161His 2/266 SNP
27 c.4123G>T het p.Glu1375X 20/320 SNP
c.4264C>T het or hom p.Arg1422Trp frequent in patients and controls new, but 2/334 alleles showed
exchange; thus, SNP
Abbreviations are as follows: Mut, mutated; het, heterozygous; hom, homozygous. CSNB mutations are annotated according to the recommendation of the
Human Genome Variation Society, with nucleotide position þ1 corresponding to the A of the translation-initiation codon ATG in the cDNA nomenclature RefSeq
NM_002420.4, 70þTRPM1. For Exon 0 and Exon 10, the respective A of the new translation initiation codon ATG was used.tomography (OCT) (extent of investigation depending on
the referring center). Thirty fragments covering 27 exons
of TRPM1 (RefSeq NM_002420.4, variant 70þTRPM113),
two fragments corresponding to two recently identiﬁed
exons (exon 10 [variant 92þTRPM113] and exon 0 [variant
109þTRPM113]) of this gene (Figure 1), and the ﬂanking
intronic regions were directly sequenced from the PCR-
ampliﬁed products (primers are listed in Table S1, available
online) with the use of a sequencing mix (BigDye Termi-
nator v1.1Cycle SequencingKit, AppliedBiosystems,Cour-
tabœuf, France) and analyzed on an automated 48-capillary
sequencer (ABI 3730 Genetic Analyzer, Applied Biosys-
tems). The resultswere interpretedbya software application
(SeqScape, Applied Biosystems).
Analysis in TRPM1 revealed causative mutations in ten
cCSNB patients (Figure 2: patient CIC00238 shown as an
example of cCSNB) with a total of 14 different mutations
(Figure 1 andTable 1). These comprise nonsensemutations,
a deletion leading to a predicted premature stop codon,
splice-sitemutations, silentmutations, andmissensemuta-
Table 3. Benign TRPM1 Variants Identified in CSNB Patients
Exon Nucleotide Exchange Protein Effect SNP ID
2 c.2T>C p.Met1Thr rs4779816
3 c.95G>A p.Ser32Asn rs2241493
11 c.1239G>A p.Thr413Thr rs1035705
16 c.1813G>A p.Val605Met rs17815774
18 c.2307T>C p.Tyr769Tyr rs12913672
c.2340T>C p.Asn780Asn rs2288242
19 c.2475C>T p.Asn825Asn rs12911350
27 c.3686A>C p.Asn1229Thr rs17227996
c.4135C>A p.Pro1379Thr rs61734298
c.4139G>A p.Val1395Ile rs3784588
c.4494T>A p.His1483Gln rs12898290
CSNB mutations are annotated according to the recommendation of the
Human Genome Variation Society, with nucleotide position þ1 corresponding
to the A of the translation-initiation codon ATG in the cDNA nomenclature
RefSeq NM_002420.4, 70þTRPM1.The Americantions. None of these changes were found among control
chromosomes (210–380 chromosomes). In those patients
from whom family members could be investigated, the
cCSNB phenotype cosegregated with the mutations and
thegenotypeswere indicative for autosomal-recessive inher-
itance (Figures 3A and 3B: three patient examples). Five
index patients (4497, 8214, CIC00612, 23625, and 758)
showed compound heterozygous mutations (Table 1).
PatientsCIC00612 and23625both revealed aheterozygous
p.Tyr72Cys substitution. From the origins of these patients,
no close familial relationship was obvious. In three index
patients (CIC00238, 691, and D0704708), an apparently
homozygous mutation was found (Table 1). Homozygosity
was proven for index patientD0704708 (Figure 3). Cosegre-
gation analysis from family members of index patient
CIC00238 revealed that another affected sister was appar-
ently homozygous for the mutation, whereas the father
washeterozygous. Twounaffected sisters and, interestingly,
themother didnot show themutation (Table 1). Theseﬁnd-
ings indicated that the patient is most likely heterozygous
for the missense mutation inherited from the father and
would have a deletion in TRPM1 or a mutation in another
gene, which would have been inherited from the mother.
Four investigated SNPs (rs4779818 in intron 1, rs4779816
in exon 2, rs2241493 in exon 3, and rs2288242 in exon
18) were apparently homozygous in the patient and the
parents. Therefore, the putative deletion could not be
deﬁned. Analyses of additional SNPs in genomic regions
of TRPM1 or screening of candidate genes may enable us
to localize the second mutation and will be investigated
in the future. The parents of patient 691 were not available
for genetic testing, and thus homozygosity could not be
proven. For two patients, 14101 and 10731, only one
heterozygous mutation was identiﬁed (Table 1). Again,
the second mutation may be a large heterozygous deletion
and thus not detectable by PCR-based sequencing. In addi-
tion, a mutation located in a second gene may disable
signaling important for nocturnal vision. Three investi-
gated SNPs (rs4779816 in exon 2, rs2241493 in exon 3,
and rs3782599 in exon 4) were apparently homozygous
in the patient and the parents, and thus the putative dele-
tion could not be deﬁned. Mutation analysis in patientJournal of Human Genetics 85, 720–729, November 13, 2009 725
Figure 4. Evolutionary Conservation of
the Altered Amino Acid Residues in Other
Orthologs
Multiple amino acid sequence alignments
show evolutionary conservation of mut-
ated residues (depicted in green). Amino
acid substitutions are highlighted in red.
The position of the respective amino acids
is shown in black numbers.14101 on other known or candidate genes (NYX, AJ278865
[MIM 300278]; GRM6, NM_000843; CABP4, NM_145200
[MIM 608965]; CACNA2D4, NM_172364 [MIM 608171];
BHLHB4, BK000274 [MIM 609331]; CACN2B, NM_000724
[MIM 600003]; GNA01, NM_020988 and NM_138736;
and TBC1D2, NM_018421 [MIM 609871]) did not reveal
any mutation. Previous mutation analyses in the simplex
case 10731 in known and candidate genes (NYX,CACNA1F,
AJ006216 [MIM 300110], GRM6, CABP4, CACNA2D4,
BHLHB4, CACN2B, GNA01, and TBC1D2) did not reveal
anymutation. Thus, for bothpatients, the secondmutation
may be found in other regions ofTRPM1, such as regulatory
sequences or unidentiﬁed exons, or may represent a dele-
tion in an as-yet-uninvestigated region of TRPM1. Alterna-
tively, the second mutation may be found in a novel
CSNB gene.
One other patient (13830) with icCSNB was compound
heterozygous for two missense changes: c.1195C>A,
causing a p.Pro399Thr substitution in exon 10, and
c.3483G>C, leading to a p.Gln1161His substitution in
exon 26, respectively (Table 2). However, the c.1195C>A
change was found in eight of 350 control chromosomes
and the c.3483G>C in two of 266. Thus, both variants
are most likely non-disease-causing variants. This is also
consistent with the fact that TRPM1 mutations in our
study speciﬁcally lead to cCSNB and not to icCSNB.
Another variant (c.4123G>T) in exon 27, leading to726 The American Journal of Human Genetics 85, 720–729, Novemba p.Glu1375X, was detected in three patients but turned
out to be a SNP (rs378489), which was detected in 20
of 320 control chromosomes. Other presumably non-
disease-causing variants were detected and are summarized
in Table 3.
The most likely pathogenic mutations identiﬁed herein
were predicted to localize at different sites of the TRP
channel. Five missense mutations, which were found in
evolutionarily conserved residues (Figure 4), one silent
mutation, and one nonsense mutation were predicted to
localize in the N-terminal intracellular part of TRPM1
(Figure 5), the function of which is not yet understood.11
All missense mutations were predicted by homology-based
programs (SIFTamd Polyphen, data not shown) to be path-
ogenic. Another silent mutation was identiﬁed in the C
terminus of TRPM1. For all of these, in addition to the
splice-site mutations, splicing could be inﬂuenced because
different splicing proteins were predicted to bind to the
mutated variants in comparison to the control (ESEﬁnder,
data not shown). In addition, mislocalization of the
mutated proteins or channel-gating defects could be the
underlying pathogenic mechanisms leading to cCSNB. In
total, ﬁve different mutations, predicted to lead to prema-
ture-termination codons in different locations of the
protein, were identiﬁed. We assume that the correspond-
ing mutant mRNAs of these alleles would probably be
subjected to nonsense-mediated decay or produce aFigure 5. Localization of TRPM1 Muta-
tions with Respect to Predicted Channel
Domains
The speciﬁc domains for the TRPM1
channel were estimated by the use of
different publications and prediction
programs14,32 (UniProtKB-Swiss-Prot).er 13, 2009
Figure 6. Schematic Drawing of Proteins
Involved in Signal Transmission from
Photoreceptors to Adjacent Bipolar Cells,
the Disruption of Which Leads to CSNB
Arrows indicate the course of the signal
transmission. In darkness, Ca2þ ions enter
the rod photoreceptors, which results in
glutamate release from the photorecep-
tors. Activated glutamate receptor acti-
vates Gao1 (arrow), which then closes the
TRPM1 channel by an unknown mecha-
nism, indicated by a question mark, and
thus ON bipolar cells are hyperpolarized.
The exact role of NYX, encoding nyctalo-
pin in this signal transduction cascade,
remains to be solved in the future (indi-
cated by a question mark).short nonfunctional form of TRPM1. Previous studies
showed that a shorter, alternatively spliced N-terminal
form of TRPM1 devoid of any putative transmembrane
segments (amino acids ~1–500) can directly interact and
suppress the activity of the full-length form by preventing
its translocation to the plasma membrane and thus
inhibiting Ca2þ entry into the cell.14 It was suggested
that under normal conditions, this mechanism regulates
the exact amount of molecules necessary for proper
channel function.
Currently, there are two genes implicated in complete
CSNB: NYX and GRM6.15–18 They code for the proteins
nyctalopin and mGluR6, respectively, which localize post-
synaptically to the photoreceptors in the retina in ON
bipolar cells.19 Whereas the function of nyctalopin is not
yet understood, mGluR6 was shown to be important for
the glutamate uptake released from the photoreceptors
(Figure 6). The most obvious phenotypical feature of
patients with cCSNB is a defect of the ON response, result-
ing in an electronegative combined rod-cone ERG, based
on a severely reduced b-wave.2 In the dark, glutamate is
released from photoreceptors, binds to mGluR6, and acti-
vates the Gao1 subunit of a heterotrimeric G protein.
This in turn leads by an unidentiﬁed mechanism to
the closure of an as-yet-unknown cation channel
(Figure 6).1,20–25 Upon light exposure, photoreceptor gluta-
mate release decreases and the ON response is initiated
with the shutting down of the G protein cascade. Subse-
quently, the cation channel opens, leading to ON bipolar
cell depolarization, giving rise to the b-wave. Mutations
in GRM6 lead to the loss of mGluR6 at the cell surface.
Modulation of glutamate released from the photoreceptors
cannot be correctly sensed by the bipolar cells, resulting in
the failure of depolarization and thus a severely reduced
b-wave.26 Recent ﬁndings in Appaloosa horses with CSNB
and a speciﬁc coat patterning caused by low expression
of a TRP channel, Trpm1, suggested that this speciﬁc
channel is speciﬁcally linked to the depolarization of theThe AmericanON bipolar cells during light exposure. However, no direct
sequencing of the Trpm1 gene was performed in the horse,
and thus the loss of ON bipolar cell function could rather
be due to a secondary effect than to the mutated Trpm1.
Nevertheless, mice lacking this channel showed the same
ocular phenotype with a severely reduced b-wave.10
Together these ﬁndings indicated that mutations in this
gene could be responsible for CSNB in patients, and
indeed, our study presented herein revealed 14 different
mutations in TRPM1 in ten different families with auto-
somal-recessive cCSNB.
Patients carrying mutations in TRPM1 reveal a similar
ocular phenotype. All showed cCSNB with selective
dysfunction of the ON bipolar pathway and OFF bipolar
pathway preservation. Most of them revealed at least one
of the following additional ocular abnormalities: myopia,
nystagmus, or strabismus. These clinical observations are
in accordance with the phenotype observed in the night-
blind Appaloosa horses also showing nystagmus and stra-
bismus. Although Bellone et al. showed downregulation
of Trpm1 in these horses,9 it will be interesting to see which
mutations in Trpm1 lead to its downregulation. Because of
the fact that the ocular phenotypewas similar in all patients
and because of the presence of a large fraction of nonsense
and splice-site mutations, we hypothesize that this form
of autosomal-recessive cCSNB is due to a lack of TRPM1
mRNA or functional TRPM1 protein on the surface, rather
than to functional alterations in the biophysical properties
of this channel. The study of animal models carrying the
identiﬁed mutations and investigation of transcript in the
retina are needed for veriﬁcation of this hypothesis.
To date, three genes have been associated with icCSNB
(CACNA1F, CABP4, and CACNA2D4),27–30 and with the
ﬁndings now reported here, there are also three genes
associated with cCSNB (NYX, GRM6, and TRPM1)15–18
(Figure 7). With respect to the other autosomal-recessive
CSNB genes identiﬁed so far, TRPM1 seems to be the
most frequently mutated gene.Journal of Human Genetics 85, 720–729, November 13, 2009 727
Figure 7. Genes Underlying CSNB
Different forms of human CSNB are classi-
ﬁed according to their mode of inheri-
tance, phenotype, and mutated genes.
Abbreviations are as follows: cCSNB,
complete CSNB; icCSNB, incomplete
CSNB; ar, autosomal recessive; ad, auto-
somal dominant. Genes are indicated in
italics and underlined. Chromosomal loca-
tion is given between brackets. The pheno-
type of patients with mutations in icCSNB
is more variable and can even lead to
progressive cone or cone-rod dystrophy.1Supplemental Data
Supplemental Data include one table and can be found with this
article online at http://www.cell.com/AJHG.
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